CD14 and COVID-19: To determine whether COVID-19 plasma exosomes induce immune responses through viral dsRNA, we treated MicroBeads selected CD4+ T cells, CD8+ T cells, and CD14+ monocytes with plasma exosomes from COVID-19 patients and non-COVID donors as well as polyinosinic-polycytidylic acid (poly(I:C)), a synthetic analog of dsRNA and a potent activator of TLR343,44, or poly(I:C) treated with an RNase.